Fluor Builds Diabetes API Manufacturing Facility for Novo Nordisk

| December 21, 2016

article image
Fluor announced on Dec. 20, 2016 that it had been awarded an engineering, procurement, construction, and construction management contract by Novo Nordisk to build a new $2-billion 830,00-sq.-ft. diabetes API manufacturing facility in Clayton, North Carolina. Construction on the new facility is expected to be completed in mid-2019.

Spotlight

Alcon

Alcon, A Division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people's lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world’s leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets and employing more than 18,000 people.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Alcon

Alcon, A Division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people's lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world’s leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets and employing more than 18,000 people.

Events